# 99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes

> **NCT05412446** · PHASE2 · COMPLETED · sponsor: **Tomsk National Research Medical Center of the Russian Academy of Sciences** · enrollment: 30 (actual)

## Conditions studied

- Breast Cancer
- Female

## Interventions

- **DRUG:** ADAPT6-SPECT

## Key facts

- **NCT ID:** NCT05412446
- **Lead sponsor:** Tomsk National Research Medical Center of the Russian Academy of Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412446, "99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05412446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*